

**Opportunity Title:** FDA Fellowship - Digital Health Technologies in Drug Development: Endpoint Analysis, Regulatory Guidance Comparison, and Systematic Literature Review

**Opportunity Reference Code:** FDA-CDER-2026-0120

**Organization** U.S. Food and Drug Administration (FDA)

**Reference Code** FDA-CDER-2026-0120

**How to Apply** *To submit your application, scroll to the bottom of this opportunity and click APPLY.*

A complete application consists of:

- An application
- Transcripts – [Click here for detailed information about acceptable transcripts](#)
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to [ORISE.FDA.CDER@orau.org](mailto:ORISE.FDA.CDER@orau.org). Please include the reference code for this opportunity in your email.

**Connect with ORISE...on the GO!** Download the new ORISE GO mobile app in the [Apple App Store](#) or [Google Play Store](#) to help you stay engaged, connected, and informed during your ORISE experience and beyond!

**Application Deadline** 8/14/2026 3:00:00 PM Eastern Time Zone

**Description** **\*Applications will be reviewed on a rolling-basis.**

**FDA Office and Location:** A research opportunity is available within the Food and Drug Administration (FDA) in The Center for Drug Evaluation and Research (CDER), Office of Medical Policy, located at White Oak, Maryland.

The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. These efforts cover more than just medicines.


**Research Project:** Through this fellowship, you will have the opportunity to join ongoing projects with the following goals:

1. Conduct a systematic literature review on the use of digital health technologies (DHTs)- in drug clinical trials.
2. Conduct in-depth characterization of select digitally-derived endpoints drawn from the DiMe Endpoint Library.
3. Systematically compare digital health guidance across key jurisdictions to identify convergences, divergences, and gaps in how guidance addresses digitally-derived endpoint measurement, validation, and evidentiary standards.

**Learning Objectives:** Under the guidance of a mentor, you will:





OAK RIDGE INSTITUTE  
FOR SCIENCE AND EDUCATION




**ORISE GO**

The ORISE GO mobile app helps you stay engaged, connected and informed during your ORISE experience – from application, to offer, through your appointment and even as an ORISE alum!

Visit ORISE GO 

GET IT ON  
 Google Play

Download on the  
 App Store

**Opportunity Title:** FDA Fellowship - Digital Health Technologies in Drug Development: Endpoint Analysis, Regulatory Guidance Comparison, and Systematic Literature Review

**Opportunity Reference Code:** FDA-CDER-2026-0120

- Acquire foundational knowledge of the evolving digital health technology (DHT) landscape in drug development by examining how digitally-derived endpoints are designed, validated, and implemented across clinical trials, therapeutic areas, and patient populations through systematic review of the scientific literature.
- Gain hands-on experience analyzing and categorizing digitally-derived endpoints by applying structured frameworks to assess endpoint definitions, technology types, clinical contexts of use, and trial characteristics across curated digital endpoint repositories such as the DiMe Endpoint Library.
- Strengthen data analysis and knowledge organization skills through the development of structured taxonomies, coding frameworks, evidence synthesis tables, and comparison matrices that support reproducible evaluation of digital health technologies and regulatory approaches.
- Enhance scientific communication and policy translation skills by synthesizing complex clinical, technical, and regulatory findings into clear, actionable deliverables

**Mentor:** The mentor for this opportunity is Hussein Ezzeldin ([hussain.ezzeldin@fda.hhs.gov](mailto:hussain.ezzeldin@fda.hhs.gov)). If you have questions about the nature of the research, please contact the mentor.

**Anticipated Appointment Start Date: October 2026.** Start date is flexible and will depend on a variety of factors.

**Appointment Length:** The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

**Level of Participation:** The appointment is full time.

**Participant Stipend:** The participant will receive a monthly stipend commensurate with educational level and experience.

**Citizenship Requirements:** This opportunity is available to U.S. citizens and Lawful Permanent Residents (LPR) only.

---

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

**Opportunity Title:** FDA Fellowship - Digital Health Technologies in Drug Development: Endpoint Analysis, Regulatory Guidance Comparison, and Systematic Literature Review

**Opportunity Reference Code:** FDA-CDER-2026-0120

### FDA Ethics Requirements



If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see [FDA Ethics for Nonemployee Scientists](#).

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

**Qualifications** The qualified candidate should be currently pursuing or have received a master's or doctoral degree in the one of the relevant fields.

**Point of Contact** [Ashley](#).

- Eligibility Requirements**
- **Citizenship:** LPR or U.S. Citizen
  - **Degree:** Master's Degree or Doctoral Degree.
  - **Discipline(s):**
    - **Engineering** ([14](#) )
    - **Life Health and Medical Sciences** ([13](#) )

**Affirmation** I am a U.S. citizen, or I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)  
and  
I have read the FDA Ethics Requirements.